Annual report pursuant to Section 13 and 15(d)

Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative)

v3.21.1
Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) - USD ($)
 12 Months Ended
Nov. 19, 2020
Dec. 12, 2019
Apr. 16, 2019
Apr. 02, 2019
Dec. 15, 2016
Feb. 19, 2016
Dec. 31, 2020
Dec. 31, 2019
Dec. 13, 2019
Entity Listings [Line Items]                  
Research and development expenses             $ 14,358,918 $ 11,234,548  
Revenue             158,333 $ 89,812  
Remaining balance lease term amount         $ 200,000        
Cooperative Research And Development Agreements [Member]                  
Entity Listings [Line Items]                  
Remaining balance lease term amount           $ 200,000      
Initial term     3 years 3 years   3 years      
Other commitment     $ 200,000            
Funds provide for support       $ 157,405          
Genentech [Member]                  
Entity Listings [Line Items]                  
Revenue             33,300    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]                  
Entity Listings [Line Items]                  
Therapeutics development award $ 4,200,000                
Proceeds from award 484,249                
Royalty payable 21,200,000                
Research and development expenses             73,400    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Upon Achievement Of Sales Milestones [Member]                  
Entity Listings [Line Items]                  
Royalty payable $ 4,200,000                
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Prepaid Expenses and Other Current Assets [Member]                  
Entity Listings [Line Items]                  
Grants Receivable             650,000.0    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Accrued Expense And Other Current Liabilities [Member]                  
Entity Listings [Line Items]                  
Other Liabilities             576,600    
Genentech Feasibility Study Agreement [Member] | Genentech [Member]                  
Entity Listings [Line Items]                  
Agreement description   Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33.3 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement.              
Deferred revenue                 $ 100,000
License Agreement [Member]                  
Entity Listings [Line Items]                  
Milestone fee             100,000    
Annual license fee             10,000    
License Agreement [Member] | Maximum [Member]                  
Entity Listings [Line Items]                  
Annual license fee             $ 50,000